KALA BIO, Inc.

KALA Healthcare Biotechnology

KALA BIO, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $3.9 million. In the quarter to June 2026, EPS grew 75.1% and free cash flow grew 80.2%, each against the same quarter a year earlier.

0.19 0.00 0.00%
Market cap
$3.7M
P/E
0.0×
Fwd P/E
−0.8×
Dividend yield
—
F-score
3/9
Altman Z
−11.18
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
0.75 3.81 7.91 6.88
Net Debt/EBITDA
(1.05) 0.67 4.86 4.20
Debt/Equity
(3.28) 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(77.36) (27.95) (0.24) (20.69)
Book value per Share
(61.54) 42.92 0.91 121.89
Free Cash Flow
(10.89) (4.56) (2.89) (1.53)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates